Comprehensive Review Maps Alzheimer's Disease Pathways and Therapeutic Strategies

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive memory loss and cognitive decline, affecting millions globally. Its complex pathology involves the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, leading to neuronal dysfunction and death. This comprehensive review synthesizes current understanding of AD's intricate molecular pathways and evaluates the landscape of emerging therapeutic interventions, aiming to identify promising targets and strategies for future drug development.

The review highlighted multiple converging molecular pathways implicated in AD, including amyloidogenesis (the formation of amyloid plaques), tauopathy (the aggregation of tau protein into tangles), neuroinflammation, and synaptic dysfunction. It noted that while early amyloid-beta (Aβ) targeting therapies have shown mixed results, with some like aducanumab demonstrating modest plaque reduction (~20-30% in some trials) but limited clinical benefit, newer monoclonal antibodies such as lecanemab and donanemab have achieved more significant Aβ clearance (up to 70-80% reduction in amyloid burden) in recent Phase III trials. > The most promising therapeutic advancements are multi-modal approaches, with tau-targeting therapies (e.g., tau aggregation inhibitors, anti-tau antibodies) and neuroinflammation modulators showing significant potential in preclinical models, often reducing pathology by 30-50% compared to untreated controls and improving cognitive metrics. * The authors emphasized that combination therapies, addressing multiple pathological hallmarks simultaneously, are emerging as a superior strategy, with preclinical studies indicating up to a 60% greater efficacy in cognitive preservation and neuronal protection than monotherapies. Furthermore, the review identified over 100 compounds currently in various stages of clinical development for AD, with approximately 25% specifically targeting tau pathology and 15% focused on modulating neuroinflammatory pathways.